Suppr超能文献

过氧化物酶体增殖物激活受体α激活对大鼠肝细胞中胆固醇稳态相关通路的影响。

Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes.

作者信息

Le Jossic-Corcos Catherine, Duclos Sandrine, Ramirez Leyla C, Zaghini Isabelle, Chevillard Grégory, Martin Pascal, Pineau Thierry, Bournot Paulette

机构信息

Laboratoire de Biologie Moléculaire et Cellulaire, GDR CNRS no. 2583, Université de Bourgogne, 6 Boulevard Gabriel, 21000 Dijon, France.

出版信息

Biochim Biophys Acta. 2004 Jul 5;1683(1-3):49-58. doi: 10.1016/j.bbalip.2004.04.004.

Abstract

Peroxisome proliferator-activated receptor alpha (PPARalpha) activation by fibrates controls expression of several genes involved in hepatic cholesterol metabolism. Other genes could be indirectly controlled in response to changes in cellular cholesterol availability. To further understand how fibrates may affect cholesterol synthesis, we investigated in parallel the changes in the metabolic pathways contributing to cholesterol homeostasis in liver. Ciprofibrate increased HMG-CoA reductase and FPP synthase mRNA levels in rat hepatocytes, together with cholesterogenesis from [(14)C] acetate and [(3)H] mevalonate. The up-regulation observed in fenofibrate- and WY-14,643-treated mice was abolished in PPARalpha-null mice, showing an essential role of PPARalpha. Among the three sterol regulatory element-binding protein (SREBP) mRNA species, only SREBP-1c level was significantly increased. In ciprofibrate-treated hepatocytes, cholesterol efflux was decreased, in parallel with cholesteryl ester storage and bile acids synthesis. As expected, AOX expression was strongly induced, supporting evidence of the peroxisome proliferation. Taken together, these results show that fibrates can cause cholesterol depletion in hepatocytes, possibly in part as a consequence of an important requirement of cholesterol for peroxisome proliferation, and increase cholesterogenesis by a compensatory phenomenon afterwards. Such cholesterogenesis regulation could occur in vivo, in species responsive to the peroxisome proliferative effect of PPARalpha ligands.

摘要

贝特类药物激活过氧化物酶体增殖物激活受体α(PPARα)可调控多个参与肝脏胆固醇代谢的基因的表达。其他基因可能会因细胞内胆固醇可用性的变化而受到间接调控。为了进一步了解贝特类药物如何影响胆固醇合成,我们同时研究了肝脏中参与胆固醇稳态的代谢途径的变化。环丙贝特可增加大鼠肝细胞中HMG-CoA还原酶和FPP合酶的mRNA水平,同时增加[(14)C]乙酸盐和[(3)H]甲羟戊酸的胆固醇生成。在PPARα基因敲除小鼠中,非诺贝特和WY-14,643处理的小鼠中观察到的上调现象消失,这表明PPARα起着至关重要的作用。在三种固醇调节元件结合蛋白(SREBP)mRNA种类中,只有SREBP-1c水平显著升高。在环丙贝特处理的肝细胞中,胆固醇流出减少,同时胆固醇酯储存和胆汁酸合成增加。正如预期的那样,AOX表达被强烈诱导,这支持了过氧化物酶体增殖的证据。综上所述,这些结果表明贝特类药物可导致肝细胞中的胆固醇消耗,这可能部分是由于过氧化物酶体增殖对胆固醇的重要需求所致,随后通过一种补偿现象增加胆固醇生成。这种胆固醇生成调节可能发生在体内,在对PPARα配体的过氧化物酶体增殖效应有反应的物种中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验